Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides a source of calories and hydration. It is metabolized to carbon dioxide and water, yielding energy. Sodium chloride provides electrolytes to maintain osmotic balance and fluid distribution.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Intravenous infusion for fluid and electrolyte replacement,Provision of caloric energy in parenteral nutrition
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion; dose depends on fluid and caloric needs, typically 100-200 m L/hour for maintenance in adults. Maximum infusion rate: 0.5 g/kg/hour dextrose.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Dextrose has a plasma half-life of approximately 1.5-2 hours under euglycemic conditions, prolonged in renal impairment (not directly applicable as it is continuously infused). Sodium and chloride have no defined half-life; they are handled by renal homeostatic mechanisms with kinetic parameters dependent on GFR and tubular function.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose is metabolized via glycolysis and the citric acid cycle to CO2 and water; sodium chloride is not metabolized.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Dextrose is completely metabolized to carbon dioxide and water; no significant renal excretion. Sodium and chloride are primarily excreted renally (99% of filtered load reabsorbed, with excess excreted in urine). Fecal/biliary elimination is negligible.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Dextrose: negligible protein binding (<1%). Sodium and chloride: not protein bound; freely ionized.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose: Vd ~0.2 L/kg (confined to extracellular fluid and rapidly equilibrates with total body water). Sodium: Vd ~0.15-0.25 L/kg (primarily extracellular). Chloride: Vd ~0.2 L/kg (extracellular). These values indicate distribution mainly in the extracellular compartment.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% bioavailability. Not administered by other routes.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: monitor fluid and electrolyte status; reduce rate if signs of fluid overload. GFR <10 m L/min: use with caution; consider alternative with lower sodium content; adjust rate based on fluid balance and serum sodium.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific adjustment for Child-Pugh class A or B; in class C, monitor glucose and electrolytes closely due to risk of hyperglycemia and fluid retention.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous infusion: neonates and children, 5 m L/kg/hour for maintenance; adjust based on serum glucose, electrolytes, and fluid status. Maximum dextrose infusion rate: 0.5 g/kg/hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use with caution due to age-related decline in renal function; start at lower rates (e.g., 50-100 m L/hour) and titrate based on fluid status, serum glucose, and electrolytes; monitor for hyperglycemia and fluid overload.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of hyperglycemia and hyperosmolar syndrome in patients with diabetes or glucose intolerance,Risk of fluid overload in patients with cardiovascular or renal impairment,Risk of electrolyte imbalances with prolonged use or large volumes,Do not administer unless solution is clear and container is intact
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to dextrose or sodium chloride,Hyperglycemia with coma,Severe hyponatremia or hypernatremia,Intracranial hemorrhage (if hypertonic solutions are used),Renal failure with oliguria or anuria
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No direct food interactions. However, the dextrose content may affect blood glucose levels; diabetic patients should monitor glucose closely. No dietary restrictions required for this intravenous solution.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
No known teratogenic risk. Dextrose and sodium chloride are physiologic components; hyperglycemia from high dextrose doses may be associated with fetal macrosomia and neonatal hypoglycemia in the third trimester.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Compatible with breastfeeding. Intravenous dextrose and sodium chloride are endogenous substances; M/P ratio not determined as they are not actively transferred into milk in significant amounts.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No systematic dose adjustment required. However, pregnancy-induced increased plasma volume and glomerular filtration rate may reduce serum glucose and sodium concentrations; monitor and adjust infusion rate to maintain euglycemia and electrolyte balance.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
This solution provides 10% dextrose (100 g/L) and 0.11% sodium chloride (11 m Eq/L Na+, 11 m Eq/L Cl-). It is hypertonic (approx. 555 m Osm/L) and should be administered via central line if prolonged therapy to avoid thrombophlebitis. Use cautiously in patients with heart failure, renal impairment, or hyperglycemia. Monitor serum glucose and electrolytes. Do not administer simultaneously with blood products due to risk of hemolysis.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This intravenous fluid contains sugar (dextrose) and salt (sodium chloride).,It is used to provide calories and maintain fluid balance when you cannot eat or drink.,Report any signs of allergic reaction: rash, itching, difficulty breathing.,Tell your nurse if you experience headache, nausea, swelling, or rapid heartbeat.,Your blood sugar and electrolyte levels will be checked regularly during treatment.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides a source of calories and hydration. It is metabolized to carbon dioxide and water, yielding energy. Sodium chloride provides electrolytes to maintain osmotic balance and fluid distribution.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and caloric needs, typically 100-200 m L/hour for maintenance in adults. Maximum infusion rate: 0.5 g/kg/hour dextrose.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. No known teratogenic risk. Dextrose and sodium chloride are physiologic components; hyperglycemia from high dextrose doses may be associated with fetal macrosomia and neonatal hypo. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.